company background image
IDRA

Idera Pharmaceuticals NasdaqCM:IDRA Stock Report

Last Price

US$0.29

Market Cap

US$18.1m

7D

-11.8%

1Y

-63.7%

Updated

10 Dec, 2022

Data

Company Financials
IDRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IDRA Stock Overview

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States.

Idera Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Idera Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.29
52 Week HighUS$0.95
52 Week LowUS$0.27
Beta1.35
1 Month Change-23.63%
3 Month Change-43.72%
1 Year Change-63.73%
3 Year Change-81.86%
5 Year Change-98.06%
Change since IPO-99.99%

Recent News & Updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Recent updates

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07
Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31
When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27
Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27
Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Nov 25
We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Shareholder Returns

IDRAUS BiotechsUS Market
7D-11.8%0.5%-2.8%
1Y-63.7%-8.6%-19.6%

Return vs Industry: IDRA underperformed the US Biotechs industry which returned -8.6% over the past year.

Return vs Market: IDRA underperformed the US Market which returned -19.6% over the past year.

Price Volatility

Is IDRA's price volatile compared to industry and market?
IDRA volatility
IDRA Average Weekly Movement10.2%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: IDRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: IDRA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198913John Taylorhttps://www.iderapharma.com

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb.

Idera Pharmaceuticals, Inc. Fundamentals Summary

How do Idera Pharmaceuticals's earnings and revenue compare to its market cap?
IDRA fundamental statistics
Market CapUS$18.10m
Earnings (TTM)-US$16.22m
Revenue (TTM)US$49.00k

372.1x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDRA income statement (TTM)
RevenueUS$49.00k
Cost of RevenueUS$9.25m
Gross Profit-US$9.20m
Other ExpensesUS$7.02m
Earnings-US$16.22m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin-18,771.43%
Net Profit Margin-33,095.92%
Debt/Equity Ratio0%

How did IDRA perform over the long term?

See historical performance and comparison